Armistice Capital discloses 9.99% Co-Diagnostics (CODX) holding via Master Fund
Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 9.99% in Co-Diagnostics (CODX), amounting to 559,706 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager. The filing indicates …